Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
To evaluate the tolerability and safety of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC; To evaluate the efficacy of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC.
Advanced Hepatocellular Carcinoma
DRUG: Adebrelimab|DRUG: Bevacizumab|DRUG: SHR-8068
Dose Limiting Toxicity, The observation period is 21 days after the first dose|Incidence and severity of grade â‰¥3 drug-related adverse events and serious adverse events of the two-drug or three-drug combination, The observation period is from the time when all informed subjects signed the informed consent to the end of the safety follow-up period, up to 2 years|Objective Response Rate, determined using RECIST v1.1 criteria, defined as best overall response (complete or partial response) across all assessment time points, At the time point of every 6 or 9 weeks, up to 2 years
Disease Control Rate, determined using RECIST v1.1 criteria, At the time point of every 6 or 9 weeks, up to 2 years|Progression-Free-Survival assessed by investigator, up to 2 years]
To evaluate the tolerability and safety of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC; To evaluate the efficacy of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC.